Cargando…

Pharmaceutical company responses to Canadian opioid advertising restrictions: A framing analysis

The pharmaceutical industry’s promotion of opioids in North America has been well-documented. Yet despite the clear consequences of improperly classifying pharmaceutical company messaging and frequently permissive approaches that allow the pharmaceutical industry to self-regulate its own advertising...

Descripción completa

Detalles Bibliográficos
Autores principales: Eisenkraft Klein, Daniel, Lexchin, Joel, Sud, Abhimanyu, Bavli, Itai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310031/
https://www.ncbi.nlm.nih.gov/pubmed/37384735
http://dx.doi.org/10.1371/journal.pone.0287861
_version_ 1785066500877451264
author Eisenkraft Klein, Daniel
Lexchin, Joel
Sud, Abhimanyu
Bavli, Itai
author_facet Eisenkraft Klein, Daniel
Lexchin, Joel
Sud, Abhimanyu
Bavli, Itai
author_sort Eisenkraft Klein, Daniel
collection PubMed
description The pharmaceutical industry’s promotion of opioids in North America has been well-documented. Yet despite the clear consequences of improperly classifying pharmaceutical company messaging and frequently permissive approaches that allow the pharmaceutical industry to self-regulate its own advertising, there has been scarce investigation to date of how pharmaceutical industry stakeholders interpret definitions of “advertising.” This study explores how variations of “marketing” and “advertising” are strategically framed by the different actors involved in the manufacturing and distribution of pharmaceutical opioids. We employed a framing analysis of industry responses to Health Canada’s letter to Canadian manufacturers and distributors of opioids requesting their commitment to voluntarily cease all marketing and advertising of opioids to health care professionals. Our findings highlight companies’ continuing efforts to frame their messaging as “information” and “education” rather than “advertising” in ways that serve their interests. This study also calls attention to the industry’s continual efforts to promote self-regulation and internal codes of conduct within a highly permissive federal regulatory framework with little concern for violations or serious consequences. While this framing often occurring out of public sight, this study highlights the subtle means through which the industry attempts to frame their promotion strategies away from “marketing”. These framing strategies have significant consequences for the pharmaceutical industry’s capacity to influence healthcare professionals, patients, and the general public.
format Online
Article
Text
id pubmed-10310031
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-103100312023-06-30 Pharmaceutical company responses to Canadian opioid advertising restrictions: A framing analysis Eisenkraft Klein, Daniel Lexchin, Joel Sud, Abhimanyu Bavli, Itai PLoS One Research Article The pharmaceutical industry’s promotion of opioids in North America has been well-documented. Yet despite the clear consequences of improperly classifying pharmaceutical company messaging and frequently permissive approaches that allow the pharmaceutical industry to self-regulate its own advertising, there has been scarce investigation to date of how pharmaceutical industry stakeholders interpret definitions of “advertising.” This study explores how variations of “marketing” and “advertising” are strategically framed by the different actors involved in the manufacturing and distribution of pharmaceutical opioids. We employed a framing analysis of industry responses to Health Canada’s letter to Canadian manufacturers and distributors of opioids requesting their commitment to voluntarily cease all marketing and advertising of opioids to health care professionals. Our findings highlight companies’ continuing efforts to frame their messaging as “information” and “education” rather than “advertising” in ways that serve their interests. This study also calls attention to the industry’s continual efforts to promote self-regulation and internal codes of conduct within a highly permissive federal regulatory framework with little concern for violations or serious consequences. While this framing often occurring out of public sight, this study highlights the subtle means through which the industry attempts to frame their promotion strategies away from “marketing”. These framing strategies have significant consequences for the pharmaceutical industry’s capacity to influence healthcare professionals, patients, and the general public. Public Library of Science 2023-06-29 /pmc/articles/PMC10310031/ /pubmed/37384735 http://dx.doi.org/10.1371/journal.pone.0287861 Text en © 2023 Eisenkraft Klein et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Eisenkraft Klein, Daniel
Lexchin, Joel
Sud, Abhimanyu
Bavli, Itai
Pharmaceutical company responses to Canadian opioid advertising restrictions: A framing analysis
title Pharmaceutical company responses to Canadian opioid advertising restrictions: A framing analysis
title_full Pharmaceutical company responses to Canadian opioid advertising restrictions: A framing analysis
title_fullStr Pharmaceutical company responses to Canadian opioid advertising restrictions: A framing analysis
title_full_unstemmed Pharmaceutical company responses to Canadian opioid advertising restrictions: A framing analysis
title_short Pharmaceutical company responses to Canadian opioid advertising restrictions: A framing analysis
title_sort pharmaceutical company responses to canadian opioid advertising restrictions: a framing analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310031/
https://www.ncbi.nlm.nih.gov/pubmed/37384735
http://dx.doi.org/10.1371/journal.pone.0287861
work_keys_str_mv AT eisenkraftkleindaniel pharmaceuticalcompanyresponsestocanadianopioidadvertisingrestrictionsaframinganalysis
AT lexchinjoel pharmaceuticalcompanyresponsestocanadianopioidadvertisingrestrictionsaframinganalysis
AT sudabhimanyu pharmaceuticalcompanyresponsestocanadianopioidadvertisingrestrictionsaframinganalysis
AT bavliitai pharmaceuticalcompanyresponsestocanadianopioidadvertisingrestrictionsaframinganalysis